摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(4-chlorophenyl)-1H-quinazolin-2-one | 313405-41-3

中文名称
——
中文别名
——
英文名称
4-(4-chlorophenyl)-1H-quinazolin-2-one
英文别名
4-(4-Chlorophenyl)quinazolin-2-ol
4-(4-chlorophenyl)-1H-quinazolin-2-one化学式
CAS
313405-41-3
化学式
C14H9ClN2O
mdl
MFCD01647269
分子量
256.691
InChiKey
PYJVJFHQHJZAID-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.6
  • 重原子数:
    18
  • 可旋转键数:
    1
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    41.5
  • 氢给体数:
    1
  • 氢受体数:
    1

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    参考文献:
    名称:
    [EN] MEDICINAL USE OF RECEPTOR LIGANDS
    [FR] UTILISATION MEDICALE DE LIGANDS RECEPTEURS
    摘要:
    公开号:
    WO2006010446A3
  • 作为产物:
    描述:
    2,2,2-trichloro-N-[2-(4-chlorobenzoyl)phenyl]acetamide 在 ammonium acetate 作用下, 以 二甲基亚砜 为溶剂, 反应 2.0h, 以97%的产率得到4-(4-chlorophenyl)-1H-quinazolin-2-one
    参考文献:
    名称:
    [EN] MEDICINAL USE OF RECEPTOR LIGANDS
    [FR] UTILISATION MEDICALE DE LIGANDS RECEPTEURS
    摘要:
    公开号:
    WO2006010446A3
点击查看最新优质反应信息

文献信息

  • MEDICINAL USE OF RECEPTOR LIGANDS
    申请人:Receveur Jean-Marie
    公开号:US20090062317A1
    公开(公告)日:2009-03-05
    Compounds of formula (I) are ligands of the melanin concentrating hormone-1 receptor (MCH-1R), useful in the treatment of diseases responsive to modulation of melanin concentrating hormone (MCH) activity, for example feeding disorders and diseases for which obesity is a risk factor (I): wherein ring B is selected from specific substituted phenyl or benz-fused 5 membered N-containing heterocycles defined in the specification; R, is attached to a ring carbon of ring B, and represents hydrogen, F, Cl, or —OCH 3 ; X is ═CH— or ═N—; L, is —CH 2 — or —CH 2 CH 2 —; L 2 is a bond, —CH 2 — or —CO—; R2 is H or C, —C 3 alkyl, or —N(R 2 ) L, —is selected from specific cyclic amino linker radicals as defined in the specification; ring A is selected from specific N-containing heterocyclic rings as defined in the specification.
    式(I)的化合物是黑素浓集激素-1受体(MCH-1R)的配体,可用于治疗对黑素浓集激素(MCH)活性调节敏感的疾病,例如进食障碍和肥胖是危险因素的疾病(式(I)):其中环B选自规定的特定取代苯基或苯并5元杂环;R附着在环B的环碳上,表示氢,F,Cl或—OCH3;X为═CH—或═N—;L为—CH2—或—CH2CH2—;L2为键,—CH2—或—CO—;R2为H或C,—C3烷基,或—N(R2)L,—选自规定的特定环状氨基连接基团。环A选自规定的特定含氮杂环。
  • COMPOUND, ORGANIC ELECTROLUMINESCENCE ELEMENT MATERIAL, INK COMPOSITION, ORGANIC ELECTROLUMINESCENCE ELEMENT, ELECTRONIC DEVICE, AND METHOD FOR PRODUCING COMPOUND
    申请人:IDEMITSU KOSAN CO., LTD.
    公开号:US20160197288A1
    公开(公告)日:2016-07-07
    A compound represented by formula (1): wherein *a, *b, R 1 , X 1 , L 1 , L 2 , n, A 1 , and A 2 are as defined in the description, and a production method of the compound represented by formula (1) are provide. In the production method, A 1 is introduced under a reaction condition in which the reactivity of Hal 2 in a compound represented by formula (I): wherein *c, *d, R 1 , X 1 , L 1 , L 2 , n, A 1 , A 2 , Hal 1 , and Hal 2 are as defined in the description, is extremely low as compared with that of Hal 1 and then A 2 which is different from A 1 is introduced under a reaction condition in which the reactivity of Hal 2 is high. The compound represented by formula (1) is formed into a layer by a coating method and meets various performance requirements of an organic EL device.
    公式(1)所表示的化合物:其中*a,*b,R1,X1,L1,L2,n,A1和A2的定义如说明书中所定义,并且提供了化合物(1)的生产方法。在生产方法中,A1在反应条件下引入,其中在化合物(I)所表示的卤素2的反应性在Hal1相比下极低,其中* c,* d,R1,X1,L1,L2,n,A1,A2,Hal1和Hal2的定义如说明书中所定义,然后在Hal2的反应性高的反应条件下引入不同于A1的A2。化合物(1)通过涂覆方法形成一层,并满足有机EL器件的各种性能要求。
  • Compound, organic electroluminescence element material, ink composition, organic electroluminescence element, electronic device, and method for producing compound
    申请人:IDEMITSU KOSAN CO., LTD.
    公开号:US10032991B2
    公开(公告)日:2018-07-24
    A compound represented by formula (1): wherein *a, *b, R1, X1, L1, L2, n, A1, and A2 are as defined in the description, and a production method of the compound represented by formula (1) are provide. In the production method, A1 is introduced under a reaction condition in which the reactivity of Hal2 in a compound represented by formula (I): wherein *c, *d, R1, X1, L1, L2, n, A1, A2, Hal1, and Hal2 are as defined in the description, is extremely low as compared with that of Hal1 and then A2 which is different from A1 is introduced under a reaction condition in which the reactivity of Hal2 is high. The compound represented by formula (1) is formed into a layer by a coating method and meets various performance requirements of an organic EL device.
    式 (1) 所代表的化合物: 其中 *a、*b、R1、X1、L1、L2、n、A1 和 A2 如说明中所定义,并提供了式 (1) 所代表化合物的生产方法。在该生产方法中,A1 是在 Hal2 在式 (I) 所代表化合物中的反应活性的反应条件下引入的: 其中 *c、*d、R1、X1、L1、L2、n、A1、A2、Hal1 和 Hal2 如说明中所定义、 与 Hal1 的反应活性相比,Hal2 的反应活性极低,然后在 Hal2 反应活性较高的反应条件下引入与 A1 不同的 A2。式(1)表示的化合物通过涂层方法形成一层,可满足有机电致发光器件的各种性能要求。
  • Chiral phosphoric acid-catalyzed asymmetric transfer hydrogenation of quinazolinones
    作者:Fan-Jie Meng、Lei Shi、Wen-Feng Jiang、Guang-Shou Feng、Xiao-Bing Lu、Zi-Biao Zhao
    DOI:10.1016/j.tetlet.2019.150947
    日期:2019.8
  • US5686560A
    申请人:——
    公开号:US5686560A
    公开(公告)日:1997-11-11
查看更多